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Background: MicroRNA (miR)-182 is frequently upregulated in cancers, has generally been viewed as an oncogene
and is possibly connected to angiogenesis. We aimed to explore what impact miR-182 has in non-small cell lung
cancer (NSCLC), and more explicitly its correlation with angiogenic markers.
Methods: From 335 unselected stage I to IIIA NSCLC carcinomas, duplicate tumor and tumor-associated stromal
cores were collected in tissue microarray blocks (TMAs). In situ hybridization (ISH) was used to detect the expression
of miR-182 in tumor cells, and immunohistochemistry (IHC) was used to detect the expression of angiogenesis
related protein markers.
Results: In univariate analyses, high tumor cell expression of miR-182 was a positive prognostic factor for patients
with squamous cell carcinoma (SCC, P = 0.042) and stage II patients (P = 0.003). Also in the multivariate analysis, high
tumor cell miR-182 expression was associated with a good prognosis in the same groups (SCC: HR 0.57, CI 95%
0.33-0.99, P = 0.048; stage II: HR 0.50, CI 95% 0.28-0.90, P = 0.020). We found significant correlations between miR-182
and the angiogenesis related markers FGF2, HIF2α and MMP-7.
Conclusion: In patients with SCC and in stage II patients, high tumor cell miR-182 expression is an independent
positive prognostic factor.
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Lung cancer is, despite a small decline in mortality re-
cent years, still the number one killer among cancers [1].
Non-small cell lung cancer (NSCLC) accounts for 80–
85% of all lung cancers. Optimization of treatment with
better surgery, cytotoxic agents and radiation therapy
has not altered the prognosis much. We are now in an
era where personalized medicine and targeted therapies
may give new hope for this patient group [2,3]. Identifi-
cation of novel molecular markers which can improve
diagnosis and prognostic stratification and serve as pos-
sible therapeutic targets will be of great importance in
the near future.
MicroRNAs (miRNAs) are small non-coding nucleo-
tides. They post-transcriptionally control the stability
and translation of mRNAs. Today, we know more than* Correspondence: Helge.Stenvold@uit.no
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reproduction in any medium, provided the or1500 different miRNAs, and each miRNA can regulate
several genes [4]. Many miRNAs are located at sites of
the genome known to be altered in cancers, and are fre-
quently up- or down regulated [5]. The differences in
miRNA expression between cancers make it possible to
develop specific miRNA profiles for different cancer
types [6].
miR-182 is one of the miRNAs often seen up-
regulated in cancers. Also in NSCLC, several studies
have reported miR-182 to be up-regulated, and it is gen-
erally regarded as an oncogene [7-11]. However, results
are conflicting concerning its role as an oncogene or
tumor suppressor. In NSCLC and other malignancies,
high miR-182 expression has been associated with cell
migration, metastatic properties of cancer cells and poor
survival [11-13]. Recent studies have, however, found
miR-182 to suppress lung cancer cell proliferation and
growth of melanoma cells [14-16].
In a recent study, we screened tumor tissues from 10
worst and 10 best prognosis NSCLC cases as well as 10al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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related miRNAs [17]. miR-182 was the only miRNA
among 281 tested to be up-regulated in all three com-
parisons: worst prognosis versus normal lung, best prog-
nosis versus normal lung and worst prognosis versus
best prognosis [17]. Besides, miR-182 appeared to be
connected to angiogenesis according to the Gene Set
Enrichment Analyses (GSEA) [17].
Based on these pilot data, we have explored the impact
of miR-182 in our large unselected cohort of 335
NSCLC cases. In situ hybridization was performed on
tissue micro array slides for high-throughput exploration
of miR-182’s prognostic impact. Since it is known that
miRNAs are highly tissue- and stage specific and miR-182,
in particular, possibly connected to angiogenesis according
to the GSEA, we aimed to explore 1) the prognostic im-
pact of miR-182 also in the NSCLC subgroups and 2) its
association with relevant angiogenic and hypoxia molecu-
lar markers.
Methods
Patients and clinical samples
Between 1990 and 2004, 371 patients with pathological
stage I to IIIA non-small cell lung cancer were diag-
nosed at the University Hospital of North Norway and
Nordland Central Hospital and treated with curative in-
tent. Resected tissues from the primary tumors in these
patients were used in our retrospective study. Out of
371 patients, 36 were excluded from the study due to
radiotherapy or chemotherapy prior to surgery (n = 10),
other malignancy within 5 years before NSCLC diagno-
sis (n = 13) or inadequate paraffin-embedded fixed tissue
blocks (n = 13). Adjuvant chemotherapy was not intro-
duced in Norway during this period (1990 – 2004).
Thus, 335 patients with complete demographic and clin-
icopathological data were eligible for this study. Of
these, postoperative radiotherapy was offered to 55 pa-
tients with non-radical surgical margins or mediastinal
lymph node disease (N2).
This report includes follow-up data as of January 10,
2011. The median follow-up time of survivors was
105 months (range 73–234). Formalin-fixed, paraffin-
embedded tumor specimens were obtained from the ar-
chives of the Departments of Clinical Pathology at the
University Hospital of North Norway and Nordland
Central Hospital. The pathological data were revised
according to the 7th edition of UICC TNM classification
of lung cancer [18]. If the morphological characteristics
for adeno- and squamous cell carcinomas were easily
recognizable, it was not always necessary to do further
examinations (IHC) of the tumor samples. If the tumors
were not well differentiated, IHC was necessary. CK7,
TTF1, p63 and CK5/6 was the markers most frequently
used. The National Data Inspection Board and theRegional Ethics Committee North (REC North) ap-
proved this study.
Microarray construction
We used a 0.6 mm-diameter stylet to sample two cores
with neoplastic tissue and two cores with tumor stroma
from different areas of the primary tumors from each
patient. Normal lung tissue localized distant from the
tumor and lung tissue sample from 20 patients without
cancer diagnosis were used as controls. The TMAs were
assembled using a tissue-arraying instrument (Beecher
Instruments, Silver Springs, Md). Eight tissue microarray
blocks were made to include all the tissue samples.
Multiple 4-μm-sections were cut with a Micron micro-
tome (HM355S) and stained by specific antibodies for
immunohistochemical analyses or stained by in situ
hybridization. The detailed methodology has been pre-
viously reported [19].
In situ hybridization (ISH)
In situ hybridization was performed following the proto-
col developed by Exiqon, Vedbaek, Denmark [20].
Digoxigenin (DIG) labelled locked nucleic acid (LNA)
modified probes from Exiqon for miR-182 (hsa-miR-
182), positive control (U6, hsa/mmu/rno) and negative
control (scramble-miR) were used in this study. Some
adjustments were done to get a specific and sensitive de-
tection of miRNA in our sections from formalin-fixed
paraffin-embedded (FFPE) TMA blocks.
We placed 4 μm sections of the TMA blocks in a heater
at 59˚C over night to attach cores to Super Frost Plus
slides. Sections were deparaffinised with xylene (3 × 5 min)
and then rehydrated with ethanol solutions (99.9% - 96% -
70%) ending up in PBS, pH 7.4. Proteinase-K (20 μg/ml)
(Exiqon, Vedbaek, Denmark) treatment was done in PK-
buffer (5 mM Tris–HCl, pH 7.5, 1 mM EDTA, 1 mM
NaCl, autoclaved) at 37˚C for 20 min in a HYBrite auto-
mated hybridizer (Abbot laboratories, IL, US). After a PBS
wash the sections were dehydrated through increasing
gradient of ethanol solutions and air-dried. The LNA-
probes were denatured by heating to 90˚C for 4 min.
Hybridization of the LNA-probe miR-182 (100nM) and
scramble miR (50nM) control was carried out in the
HYBrite automated hybridizer at 50˚C for 60 min. The
positive control U6 (1nM) was hybridized at 55˚C for
60 min. Stringent washes was performed in pre-heated
SSC buffers, 1 × 5 min in 5x SSC, 2 × 5 min in 1× SSC
and 0,2× SSC. Sections were blocked against unspecific
binding in blocking solution from DIG wash and Block
Buffer set (Roche, Mannheim, Germany) for 15 min at
room temperature (RT). Alkaline phosphatase (AP)-con-
jugated anti-DIG (Roche) 1:800 was incubated for 60 min
at RT for immunologic detection. After PBS-T wash the
substrate enzymatic reaction was carried out with NBT/
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The reaction was stopped with a 2 × 5 min wash in
KTBT buffer (50 mM Tris–HCl, 150 mM NaCl, 10 mM
KCl). Sections were counter stained with nuclear fast
red (WALDECK, ZE-012-250) at RT for 1 min and then
rinsed in tap water. Dehydration followed through in-
creasing gradient of ethanol solutions and finally mount-
ing with Histokitt mounting medium (Assistant-Histokitt,
1025/250).Immunohistochemistry (IHC)
We used data from previous publications with the follow-
ing antibodies for correlation analyses: VEGF (−A, –C, -D,
R-1, R-2, R-3), PDGF (−A, -B, –C, -D, R-α, R-β), FGF (−2,
R-1), Notch (−1, -2), Jagged1, DLL4, Hif (−1α, -2α),
GLUT-1, LDH5, CAIX, PHD (−1, -2, -3), FIH, Ang
(−1, -2, -4), Tie-2 and MMP (−2, -7, -9). Detailed IHC pro-
cedures for the antibodies which correlated significantly
with miR-182 (FGF2, Hif2α and MMP-7) have been previ-
ously published [21-23].Scoring of ISH
Representative viable tissue sections were scored semi-
quantitatively by light microscopy. The dominant stain-
ing intensity in tumor cells was scored as 0 = negative,
1 = weak, 2 = intermediate or 3 = strong (Figure 1). The
TMA cores were scored anonymously and independently
by one experienced pathologist and one oncologist. InFigure 1 In situ hybridization (ISH) analysis of non-small-cell lung can
from 0–3 in tumor cells. A: score 0; B: score 1; C: score 2; D; score 3.case of disagreement, the slides were reexamined and
consensus was reached by the observers.
Mean score for duplicate cores from each individual
was calculated in tumor epithelial cells. We then catego-
rized the staining into high and low expression. High ex-
pression in tumor cells was defined as score >0.
Statistical methods
All statistical analyses were performed using the stati-
stical package SPSS (Chicago, IL), version 19.0. The
chi-square test and the Fisher exact test were used to
examine the association between molecular marker ex-
pression and the clinicopathological markers. Correla-
tions between markers were assessed using Spearman’s
rank correlation. Univariate analyses were done using
the Kaplan-Meier method, and statistical significance be-
tween survival curves was assessed by the log-rank test.
Disease-specific survival (DSS) was defined as time from
surgery to lung cancer death. Variables of significant
value from the univariate analyses were entered into
multivariate analysis using the backward stepwise Cox
regression analysis. A P < 0.05 was considered statisti-
cally significant.
Ethics
The National Data Inspection Board and the Regional
Ethics Committee North (REC North) approved this
study. Information and subsequent written consent from
patients was considered, but as this was a retrospectivecer. Scoring intensities based on blue cytoplasmatic staining graded
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of the patients having to be reminded about the death
rate of the disease and the possible raising of unrealistic
hope for the individual, The Norwegian Data Inspection
Board and REC North specifically waived the need for
consent. All the patient data were anonymized after col-
lecting the clinicopathological variables for each patient
and before doing the statistical analyses.Results
Patient characteristics
Demographic, clinical and histopathological variables are
listed in Table 1. The median patient age was 67 (range
28–85) and the majority were male (76%). Most patients
(95%) were current or previous smokers. The NSCLC
tumors comprised 191 squamous cell carcinomas (SCC),
113 adenocarcinomas (AC) including 18 bronchioloalve-
olar carcinomas (BAC) and 31 large-cell carcinomas
(LCC).Expression of miR-182 and correlations
miR-182 was homogenously expressed mainly in the
cytoplasm of tumor cells. There was also some unspe-
cific nuclear staining (Figure 1). The scoring was based
on cytoplasmic staining. There was no staining of stro-
mal cells, except for weak nuclear staining of some
fibroblasts.
We tested correlations between miR-182 and angiogenic
and hypoxia molecular markers. We found significant cor-
relations between miR-182 and FGF2 (r = −0.147; P =
0.010), HIF2α (r = 0.115; P = 0.047) and MMP-7 (r = 0.172;
P = 0.003).Univariate analysis
As shown in Table 1, the clinicopathological variables per-
formance status (P = 0.016), histology (P = 0.028), tumor
differentiation (P < 0.001), surgical procedure (P = 0.007),
pathological stage (P < 0.001), tumor status (P < 0.001),
nodal status (P < 0.001) and vascular infiltration (P = 0.001)
were significant prognostic indicators for DSS.
The results from the univariate analyses on miR-182
are presented in Table 2 and Figures 2 and 3. In the
whole cohort, there was a tendency towards a better
prognosis for those with tumors overexpressing miR-
182 (P = 0.062, Figure 2). In subgroup analyses, patients
with stage II disease had a significantly improved progno-
sis if they overexpressed miR-182 (P = 0.003, Figure 3E).
In the histological subgroup SCC, high tumor cell miR-
182 expression was associated with superior prognosis
when compared to low expression (P = 0.042, Figure 3A),
while for large cell carcinomas the trend was opposite
(Figure 3C).Multivariate analysis
In the total cohort, performance status (P = 0.008), hist-
ology (P = 0.001), tumor differentiation (P = 0.007),
tumor status (P = 0.007), nodal status (P = 0.022) and
vascular infiltration (P = 0.004) all were independent
prognostic factors.
Results of the multivariate analysis for miR-182 ex-
pression are presented in Table 2. Examining the total
material, high miR-182 expression tended towards an in-
dependent association with a better prognosis (HR 0.73,
CI 95% 0.50-1.06, P = 0.098). Among stage II patients,
however, high tumor cell expression of miR-182 was an
independent positive prognostic factor (HR 0.50, CI 95%
0.28-0.90, P = 0.020). Also in SCC, patients with a high
miR-182 expression had an independent favorable out-
come (HR 0.57, CI 95% 0.33-0.99, P = 0.048).Co-expression of miR-182 with FGF2 and MMP-7
Among markers examined for correlations with miR-
182, FGF2 and MMP-7 showed the strongest correla-
tions. We assessed the co-expression combinations be-
tween miR-182 and FGF2 and MMP-7, respectively. The
co-expression of low miR-182/high FGF2 was associated
with poor survival (P = 0.017) as shown in Figure 4A.
The combination showed an independently significant
adverse prognosis compared to high miR-182/low FGF2
(HR 1.92, P = 0.015, Table 3). Patients expressing high
miR-182/high MMP-7 had a better survival than other
combinations (P = 0.036, Figure 4B). In the multivariate
analyses, high miR-182/high MMP-7 showed an inde-
pendently better prognosis than low miR-182/low MMP-7
(HR 0.49, P = 0.015, Table 3). In the SCC subgroup, we
found an even bigger difference between these groups
both in univariate and multivariate analyses (Figure 4C,
Table 3).Discussion
In a large unselected cohort of NSCLC patients we found
miR-182 to be an independent positive prognostic factor
in stage II patients and in patients with squamous cell car-
cinoma. We are, to our knowledge, the first group evaluat-
ing the prognostic impact of miR-182 in NSCLC using in
situ hybridization.
Barshack and coworkers showed that miR-182 was
over-expressed in primary lung tumors relative to metas-
tases to the lung [24]. In another study by the same group,
a set of different miRNAs could be used to differentiate
hepatocellular carcinomas from metastatic tumors in the
liver [25]. miRNA expression differs between tumor types,
within the same tumor type in different patients and be-
tween primary tumors and metastases. Hence, it may not
be surprising to find miR-182 to have divergent impact in
different stages of NSCLC.
Table 1 Patient characteristics and their variables as
predictors for disease-spesific survival in 335 NSCLC






n (%) months %
Age
≤ 65 years 156 (47) 98 55 0.42
>65 years 179 (53) NR 60
Sex
Female 82 (24) 190 64 0.22
Male 253 (76) 98 56
Smoking
Never 15 (5) 19 43 0.26
Current 215 (64) NR 60
Former 105 (31) 84 55
Performance status
PS 0 197 (59) NR 63 0.016
PS 1 120 (36) 64 52
PS 2 18 (5) 25 33
Weight loss
< 10% 303 (90) 190 58 0.76
> 10% 32 (10) 98 57
Histology
SCC 191 (57) NR 66 0.028
Adenocarcinoma 113 (34) 54 46
LCC 31 (9) 98 56
Differentiation
Poor 138 (41) 47 47 < 0.001
Moderate 144 (43) 190 65




243 (73) 190 62 0.007
Pneumonectomy 92 (27) 37 47
Pathological stage
I 157 (47) NR 61 < 0.001
II 136 (40) 62 51
IIIa 42 (13) 17 23
Tumor status
1 85 (25) 190 75 < 0.001
2 188 (56) 84 57
3 62 (19) 25 36
Nodal status
0 232 (69) NR 67 < 0.001
1 76 (23) 35 43
2 27 (8) 18 18
Table 1 Patient characteristics and their variables as
predictors for disease-spesific survival in 335 NSCLC
patients (univariate analyses; log-rank test) (Continued)
Surgical margins
Free 307 (92) 190 59 0.37
Not free 28 (8) 47 48
Vascular infiltration
No 284 (85) 190 62 0.001
Yes 51 (15) 27 33
Statistically significant results in bold font.
*Wedge, n = 10.
Abbreviations: NR not reached, PS performance status, SCC squamos cell
carcinoma, LCC large-cell carcinoma. Adenocarcinoma including cases with
bronchioloalveolar carcinoma.
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omas and SCC of the lung are separate lung cancer
entities, have dissimilar features and may respond differ-
ently to therapy. Targeted drugs with specific effects in
certain histological subgroups have been developed. Cer-
tain miRNA-signatures can differentiate SCC from non-
SCC and may facilitate the distinction between them
[26]. Demonstrating a significant prognostic effect by
miR-182 in SCC and not in adenocarcinomas under-
scores the diversity between the histological subgroups.
In a previous published paper from our group [27], we
explored the impact of miR-155 in the same cohort. We
found this miRNA to be very stage- and tissue specific,
with a significant impact on survival only in node posi-
tive SCC patients.
miR-182 has been regarded as an oncogene in most con-
texts. In a cohort of 253 glioma patients, high miR-182 ex-
pression was found to be a negative prognostic factor [12].
In melanoma cell lines, Segura and coworkers showed that
high miR-182 expression stimulated migration and sur-
vival. The same group treated liver metastases in mice with
anti-miR-182 and obtained a lower tumor burden and a
lower mir-182-level than in untreated mice [13,28]. Also
in breast tumors and cervical cancers miR-182 seems to
have an oncogenic impact [29,30].
There are other studies that have identified miR-182
as a tumor suppressor. Kong et al. found miR-182 to be
underexpressed in human gastric cancer cell lines. They
showed that the oncogene cAMP responsive element
binding protein 1 (CREB1) is a target of miR-182, and
that high levels of miR-182 leads to lower levels of
CREB1 and suppressed gastric adenocarcinoma cell
growth [31]. In melanoma cell lines, Poell et al. found
miR-182 to be a strong inhibitor of cell proliferation
[14]. Yan and coworkers found similar effects in uveal
melanoma cells, where they identified MITF, BCL2 and
cyclin D2 as potential targets of miR-182. Transfection
of miR-182 into cultured uveal melanoma cells led to a
Table 2 miR-182 in tumor cells and stroma as predictors for disease-specific survival in NSCLC patients (univariate
analysis; log-rank test) and results of Cox regression analysis summarizing significant independent prognostic factors
Characteristics Pts (n) Pts (%) Median survival (months) 5-year survival (%) Univariate (P) Multi-variate (P) HR (95% CI)
Total (n = 335) 0.062 0.098 0.73
Low 190 57 98 55 (0.50-1.06)
High 115 34 NR 62
Missing 30 9
Pathological stage
Stage I (n = 143) 0.97 NE NE
Low 87 61 190 73
High 56 39 NR 73
Stage II (n = 127) 0.003 0.020 0.50
Low 80 63 33 39 0.28-0.90
High 47 37 NR 63
Stage III (n = 35) 0.69 NE NE
Low 23 66 23 39
High 12 34 15 17
Histology
SCC (n = 172) 0.042 0.048 0.57
Low 104 60 NR 58 0.33-0.99
High 68 40 NR 74
AC (n = 106) 0.316 NE NE
Low 69 65 47 45
High 37 35 57 50
LCC (n = 27) 0.285 NE NE
Low 17 63 NR 80
High 10 37 58 39
Statistically significant results in bold font.
Abbreviations: NR not reached, PS performance status, SCC squamous cell carcinoma, AC adenocarcinoma, LCC large-cell carcinoma, NE not entered due to
insignificance. Adenocarcinoma including cases with bronchioloalveolar carcinoma.
Figure 2 Disease-specific survival curves according to tumor
cell expression of miR-182 in the whole cohort of patients.
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siveness [16].
In lung cancer, data on miR-182 have been conflicting
regarding its prognostic role. In 70 lung cancer tissue
samples, Zhu and coworkers observed an association be-
tween high expression of the members of the miR-183
family (miR-96, miR-182 and miR-183) and poor overall
survival [11]. In contrast, two in vitro studies using cell
lines did not support the notion of miR-182 exerting
an oncogene role in lung cancer. Sun et al. found
miR-182, through regulation of RGS17, to suppresses
lung tumorigenesis [15]. Consistently, Zhang and co-
workers reported miR-182 to inhibit proliferation and
invasion of human lung adenocarcinoma cells via its
effect on human cortical actin-associated protein
(CTTN) [32].
miR-182 has a number of target genes, and it is evident
that the regulation of these genes can result in both inhib-
ition and stimulation of tumorigenesis. In NSCLC, our
results suggest that tumor inhibiting miR-182 features
dominate and thus make this miRNA a favorable prognos-
tic factor.
Figure 3 Disease-specific survival curves according to tumor cell expression of A) miR-182 in SCC, B) miR-182 in AC, C) miR-182 in LCC,
D) miR-182 in stage I patients, E) miR-182 in stage II patients, F) miR-182 in stage III patients.
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from the GSEA [17], we investigated the correlation be-
tween miR-182 and a set of angiogenesis-related protein
markers. There was a negative correlation between miR-
182 and FGF2. Our group has published data on FGF2,
which identify this marker as an independent negative
prognostic factor in lung cancer cells [22]. Fibroblast
growth factor receptor substrate 2 (FRS2) is a down-
stream mediator of the fibroblast growth factor pathway
and is a target gene of miR-182. FRS2 is thought to in-
duce tumor progression through stimulation of an-
giogenesis [17,33]. In our total NSCLC cohort, the
coexpression between miR-182 and FGF2 showed an in-
dependent significantly worse prognosis for low miR-
182/high FGF2 than for high miR-182/low FGF2 (P =
0.015, Table 3).
A correlation was also detected between miR-182 and
MMP-7. In a previous paper, our group found high
MMP-7 expression to be an independent favorable prog-
nostic factor in this same NSCLC cohort [23]. When
examining coexpression of the two variables, those with
high miR-182 and high MMP-7 expression had anindependently better survival than those with low miR-
182/low MMP-7 expression (HR 0.49, P = 0.015). When
stratifying on histology, the SCC patients with high/high
expression had a remarkably better prognosis than the rest
of the groups (HR 0.26, P = 0.012, Table 3).
To our knowledge, there are no published data linking
miR-182 and MMP-7. Few studies have described the
connection between FGF2 and MMP-7 [34,35]. Based
on our strong results from the co-variations between
miR-182 and particularly MMP-7, it would be interest-
ing to see functional studies exploring potential relations
between these two markers.
In our previous pilot study on miRNA signatures [17],
miR-182 appeared as an oncogene since it was up-
regulated in short vs long term NSCLC survivors and in
NSCLC vs normal tissues. In our large unselected
NSCLC cohort presented herein, we surprisingly ob-
served that high miR-182 expression is associated with
improved survival, at least in subgroups of patients with
NSCLC. It has to be kept in mind that the explorative
study was based on a small sample, only 20 NSCLC
cases and 10 normal lung tissues. Hence, the contrasting
Figure 4 Disease-specific survival curves according to tumor cell co-expression of miR-182 and A) FGF2 in the whole cohort of patients,
B) MMP-7 in the whole cohort of patients, C) MMP-7 in SCC, and D) MMP-7 in AC.
Table 3 Results of Cox regression analysis summarizing
co-expressions of miR-182 with FGF2 and MMP-7, respectively
Hazard ratio 95% CI P
Co-expression of miR-182/FGF2 0.021
High miR-182/low FGF2 1.00
High miR-182/high FGF2 and
low miR-182/low FGF2
1.26 0.74-2.13 0.39
Low miR-182/high FGF2 1.92 1.14-3.24 0.015
Co-expression of miR-182/MMP-7 0.032
Low miR-182/low MMP-7 1.00
Low miR-182/high MMP-7 and
high miR-182/low MMP-7
0.71 0.48-1.05 0.086




Low miR-182/low MMP-7 1.00
Low miR-182/high MMP-7 and
high miR-182/low MMP-7
0.80 0.46-1.37 0.41
High miR-182/high MMP-7 0.26 0.090-0.74 0.012
Statistically significant results in bold font.
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the explorative study. Besides, in the present study the
favorable prognostic impact by miR-182 was seen in
subgroups of NSCLC patients, and assessments were
tissue specific (only in tumor cells) using in situ
hybridization and not real time qPCR, as in the pilot
study [17]. When using qPCR a contribution from the
stromal compartment will influence the result, and the
stromal expression of miR-182 may be different from
that of the tumor cells.
Conclusion
In conclusion, miR-182 tended to be a favorable prog-
nostic factor in the total NSCLC cohort. Moreover, in
stage II and in SCC patients we found miR-182 to have
tumor suppressor properties. Nevertheless, our study
must be regarded as hypotheses generating, and needs
to be confirmed in other cohorts and functional studies.
We found a weak, but significant association between
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MMP-7. It would be interesting to see further studies
exploring these associations.
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